IP Library › Granted Patent US 7,153,499
Granted Patent B2
US 7,153,499 · App. 10/430,506 · Granted Dec 26, 2006

Vaccine immunotherapy for immune suppressed patients

Assignee: IRx Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,153,499
App. No.
10/430,506
Granted
Dec 26, 2006
Kind
B2
Abstract

The present invention provides a formulation for inhibiting metastasis which includes 150–600 units of IL-2, a nonsteroidal anti-inflammatory drug (NSAID), and cyclophosphamide. The present invention further provides a formulation for inhibiting metastasis that includes IL-1, IL-2, IL-6, IL-8, δ-IFN and TNF-α.

Claims (2)

1. A formulation consisting of 150–600 units of IL-2, a non-steroidal anti-inflammatory drug (NSAID) and cyclophosphamide.

2. A formulation consisting of IL-1, IL-2, IL-6, IL-8, IFN-γ and TNF-α.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2019
From: IRX THERAPEUTICS, INC.
To: BROOKLYN IMMUNOTHERAPEUTICS LLC
Reel/Frame 048424/0096 →
RELEASE OF SECURITY INTEREST Recorded Dec 13, 2013
From: KOHN & ASSOCIATES PLLC; KOHN, KENNETH I.
To: UNIVERSITY OF SOUTH FLORIDA; IRX THERAPEUTICS, INC.
Reel/Frame 031782/0396 →
LIEN Recorded Aug 19, 2013
From: UNIVERSITY OF SOUTH FLORIDA; IRX THERAPEUTICS, INC.
To: KOHN & ASSOCIATES PLLC
Reel/Frame 031035/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2013
From: HADDEN, JOHN W.
To: IRX THERAPEUTICS, INC.
Reel/Frame 029740/0160 →
Continuity (3)
Continuation 1001512300 · Oct 26, 2001
Provisional Application 6024391200 · Oct 27, 2000
Related Publication 20030206885A1 · Nov 6, 2003